Daily Endocrinology Research Analysis
Three standout studies in endocrinology this cycle: single-cell immune transcriptomics maps an inflammatory–inhibitory continuum across type 1 diabetes and LADA with actionable targets; triangulated imaging and Mendelian randomization implicate pancreatic fibrosis causally in type 2 diabetes; and an international multicenter cohort supports minimally invasive adrenalectomy for large pheochromocytomas. Together, they span mechanism-to-practice and could redirect therapeutic and surgical strategie
Summary
Three standout studies in endocrinology this cycle: single-cell immune transcriptomics maps an inflammatory–inhibitory continuum across type 1 diabetes and LADA with actionable targets; triangulated imaging and Mendelian randomization implicate pancreatic fibrosis causally in type 2 diabetes; and an international multicenter cohort supports minimally invasive adrenalectomy for large pheochromocytomas. Together, they span mechanism-to-practice and could redirect therapeutic and surgical strategies.
Research Themes
- Immune set-point mechanisms in autoimmune diabetes (T1D/LADA)
- Causal role of pancreatic fibrosis in type 2 diabetes
- Minimally invasive surgery for large pheochromocytoma
Selected Articles
1. Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.
Single-cell profiling of >400,000 PBMCs across new-onset T1D, LADA, and controls maps a spectrum from high NF-κB/EGFR-driven inflammation (T1D) to restrained effector activity via HLA-C–KIR checkpoints (LADA). The study proposes the NF-κB/EGFR–JAK/STAT gradient and HLA-C–KIR axis as tractable therapeutic targets to preserve β-cell function.
Impact: This mechanistic atlas reframes autoimmune diabetes as an adjustable immune set point, highlighting druggable pathways/checkpoints with potential to stratify and tailor immunomodulation across T1D and LADA.
Clinical Implications: Suggests biomarker-guided stratification (e.g., NF-κB/EGFR activity, HLA-C–KIR interactions) to tailor immunotherapies aimed at preserving β-cell function, and cautions that peripheral immune qualitatives—not cell counts—may drive heterogeneity.
Key Findings
- PBMC composition was similar across cohorts; qualitative signaling differences underlay disease heterogeneity.
- T1D showed pan-lineage NF-κB/EGFR/MAPK/hypoxia activation with TNF-centered communication and enhanced MHC signaling.
- LADA exhibited suppressed NF-κB/EGFR, moderate JAK/STAT tone, reinforced HLA-C–KIR inhibitory checkpoints, and stabilized CD8+ T cell synapses via HLA-C–CD8.
- Single-cell V(D)J analysis revealed multiclonal, patient-unique repertoires, emphasizing signaling context over receptor convergence.
Methodological Strengths
- Large-scale single-cell RNA-seq with paired TCR/BCR V(D)J profiling across patient groups
- Systems-level pathway and cell–cell communication analyses identifying actionable axes
Limitations
- Peripheral blood may not fully represent pancreatic islet immunity
- Cross-sectional design; functional in vivo validation of targets not reported
Future Directions: Prospective studies integrating islet tissue, longitudinal immune profiling, and interventional testing of the NF-κB/EGFR and HLA-C–KIR axes.
Autoimmune diabetes encompasses rapidly progressive type 1 diabetes mellitus (T1D) and indolent latent autoimmune diabetes in adults (LADA), representing distinct inflammatory set points along a shared autoimmune spectrum. Yet the immunological mechanisms that determine these divergent inflammatory states remain unresolved. We performed single-cell RNA sequencing with paired T and B cell receptor profiling on over 400,000 peripheral blood mononuclear cells (PBMCs) from patients with LADA, newly diagnosed T1D, and healthy controls. PBMC composition was comparable across cohorts, indicating that qualitative rather than quantitative immune differences underlie disease heterogeneity. In T1D, pan-lineage activation of NF-κB, EGFR, MAPK, and hypoxia pathways, coupled with a TNF-centered communication hub, enhanced MHC signaling, and disrupted adhesion, promoted systemic inflammation. LADA, by contrast, exhibited global suppression of NF-κB/EGFR activity, retention of moderate JAK/STAT tone, reinforced natural killer cell inhibitory checkpoints via HLA-C-KIR2DL3/3DL1 interaction, and stabilized CD8⁺ T cell synapses through HLA-C-CD8 binding, collectively restraining effector activation. Single-cell V(D)J analysis revealed multiclonal, patient-unique adaptive repertoires, emphasizing the primacy of signaling context over receptor convergence. These findings define autoimmune diabetes as an inflammatory-inhibitory set-point continuum, positioning the NF-κB/EGFR-JAK/STAT gradient and HLA-C-KIR axis as potential therapeutic targets to preserve residual β-cell function.
2. Transcriptional coregulator ZMIZ1 modulates estrogen responses that are essential for healthy endometrial function.
ZMIZ1, positioned at an ESR1 super-enhancer, is required for endometrial proliferation, decidualization, and proper estrogen/progesterone responses. Uterine Zmiz1 ablation in mice causes infertility, impaired decidual response, reduced PGR expression, and accelerated uterine fibrosis, establishing ZMIZ1 as a key ESR1 coregulator.
Impact: By defining ZMIZ1 as an estrogen receptor coregulator essential for endometrial function, this work offers mechanistic insight with implications for infertility, endometriosis, and endometrial cancer.
Clinical Implications: Suggests ZMIZ1/ESR1 axis as a potential biomarker and therapeutic target in disorders of endometrial receptivity and function; may inform stratification and targeted modulation of estrogen signaling.
Key Findings
- ZMIZ1 colocalizes with an ESR1-binding super-enhancer; mutations observed in endometrial cancer and reduced expression trends in endometriosis.
- Uterine Zmiz1 deletion in mice causes infertility, impaired hormonally induced decidualization, reduced stromal PGR, and accelerated uterine fibrosis.
- Transcriptomics show reduced E2F/CCNA2/FOXM1 signaling; estrogen challenge elicits diminished amplitude of estrogen-responsive genes.
Methodological Strengths
- Integration of human endometrial data, in vitro knockdown, and uterine conditional knockout mouse models
- Multimodal readouts including histology, hormone challenges, receptor expression, and transcriptomics
Limitations
- Preclinical nature limits immediate clinical generalizability
- Rescue experiments and therapeutic modulation of ZMIZ1 were not reported
Future Directions: Evaluate ZMIZ1 as a clinical biomarker of endometrial receptivity and test pharmacologic or gene-targeted modulation of the ZMIZ1/ESR1 axis.
Estrogen is a critical regulator of endometrial health. Aberrant estrogen stimulation can result in infertility, endometrial cancer, and endometriosis. Here, we identified Zinc Finger MIZ-Type Containing 1 (Zmiz1) as a coregulator of uterine estrogen signaling. ZMIZ1 is colocalized with an estrogen receptor α-binding (ESR1-binding) super enhancer. ZMIZ1 mutations are found in endometrial cancer and its RNA levels trend toward reduction in endometrium of patients with endometriosis. ZMIZ1 is dynamically expressed in human endometrial tissues during the menstrual cycle. Disrupting ZMIZ1 in cultured human endometrial stromal cells resulted in impaired cell proliferation and decidual differentiation. Ablation of Zmiz1 using the PgrCre mouse (Zmiz1d/d) resulted in infertility and accelerated age-dependent uterine fibrosis. Zmiz1d/d mice showed reduced ovulation and progesterone levels while maintaining normal serum prolactin during pregnancy. Uteri of Zmiz1d/d mice were unable to undergo a hormonally induced decidual response, had decreased expression of stromal progesterone receptor (PGR) and decreased stromal and epithelial cell proliferation. Analysis of the transcriptome of Zmiz1d/d mouse uteri showed decreased E2F, CCNA2, and FOXM1 signaling. Challenging ovariectomized Zmiz1d/d mice with estrogen resulted in a decreased amplitude of some estrogen-regulated gene responses. Our findings demonstrate the importance of ZMIZ1 as an ESR1 coregulator in uterine biology and pathology.
3. Multiorgan Fibrosis and Risk of Type 2 Diabetes: Genetic and Observational Evidence Highlighting a Causal Role of Pancreatic Fibrosis.
A CT case-control study and Mendelian randomization converge to implicate pancreatic—rather than hepatic or myocardial—fibrosis in type 2 diabetes risk. The organ-specific association and genetic causality nominate pancreatic fibrosis as a mechanistically plausible, targetable pathway to preserve β-cell function.
Impact: Establishing pancreatic fibrosis as a likely causal risk factor for T2D reframes disease pathogenesis and opens avenues for imaging-based risk stratification and anti-fibrotic interventions.
Clinical Implications: Supports evaluating pancreatic fibrosis as a biomarker for T2D risk and motivates trials of anti-fibrotic or fibrosis-modifying therapies aimed at β-cell preservation.
Key Findings
- CT-based case-control: Greater pancreatic extracellular volume fraction associated with T2D (adjusted OR per 1-SD: 1.64; 95% CI 1.00–2.68), independent of confounders.
- Mendelian randomization: Genetically predicted pancreatic fibrosis increases T2D risk (OR per 1-SD: 1.43; 95% CI 1.09–1.89).
- No association for liver or myocardial fibrosis in either observational or genetic analyses, indicating organ specificity.
Methodological Strengths
- Triangulation: imaging-based case-control plus large-scale Mendelian randomization
- Multiorgan comparison demonstrating organ specificity
Limitations
- Small CT case-control sample; extracellular volume fraction is an indirect fibrosis surrogate
- Potential MR pleiotropy and measurement heterogeneity across GWAS sources
Future Directions: Prospective imaging cohorts and interventional trials testing anti-fibrotic strategies to prevent T2D onset or preserve β-cell function.
UNLABELLED: Pancreatic fibrosis has been proposed as a contributor to type 2 diabetes (T2D) by impairing islet function, but whether it plays a causal role remains unclear. We investigated this question using two complementary approaches. First, we performed a computed tomography-based retrospective case-control study (T2D case patients: n = 58; control participants: n = 58) assessing extracellular volume fraction as a marker of fibrosis in the pancreas, liver, and myocardium. Greater pancreatic fibrosis was associated with T2D (adjusted odds ratio [OR] per 1 [SD] increase: 1.64; 95% CI 1.00-2.68), independent of age, sex, BMI, liver fibrosis, and myocardial fibrosis. Second, we conducted a Mendelian randomization analysis using genome-wide association study (GWAS) data on multiorgan fibrosis derived from MRI in the UK Biobank (n = 43,881), along with T2D GWAS data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium (n = 242,283 T2D case patients and 1,569,734 control participants). Genetically predicted pancreatic fibrosis levels were associated with an increased T2D risk (OR per 1-SD increase: 1.43; 95% CI 1.09-1.89), whereas liver and myocardial fibrosis levels showed no associations. These findings support a potential causal and organ-specific role of pancreatic fibrosis in the pathogenesis of T2D, highlighting pancreatic fibrosis as a mechanistically plausible and potentially targetable target in diabetes prevention. ARTICLE HIGHLIGHTS: Pancreatic, but not liver or myocardial, fibrosis is specifically and independently linked to type 2 diabetes. Mendelian randomization analysis reveals a causal role of pancreatic fibrosis in diabetes development. Pancreatic fibrosis might be a potential therapeutic target to preserve β-cell function and prevent diabetes.